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The natural polyether ionophore antibiotics might be important chemotherapeutic agents for the treat-
ment of cancer. In this article, the pharmacology and anticancer activity of the polyether ionophores
undergoing pre-clinical evaluation are reviewed. Most of polyether ionophores have shown potent activ-
ity against the proliferation of various cancer cells, including those that display multidrug resistance
(MDR) and cancer stem cells (CSC). The mechanism underlying the anticancer activity of ionophore
agents can be related to their ability to form complexes with metal cations and transport them across
cellular and subcellular membranes. Increasing evidence shows that the anticancer activity of polyether
ionophores may be a consequence of the induction of apoptosis leading to apoptotic cell death, arresting
cell cycle progression, induction of the cell oxidative stress, loss of mitochondrial membrane potential,
reversion of MDR, synergistic anticancer effect with other anticancer drugs, etc. Continued investigation
of the mechanisms of action and development of new polyether ionophores and their derivatives may
provide more effective therapeutic drugs for cancer treatments.
 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.According to the World Health Organization (WHO) cancer is a
leading cause of death worldwide, accounting for 7.6 million
deaths (around 13% of all deaths) in 2008. Projections are even
more disturbing because deaths from cancer are expected to rise
to over 13.1 million in 2030.1
Over the last few decades, natural products have played a very
important role as established cancer chemotherapeutic agents,
either in their unmodiﬁed (naturally occurring) or synthetically
modiﬁed forms.2 Microorganisms are a proliﬁc source of structur-
ally diverse bioactive metabolites and have yielded some of the
most important products in the pharmaceutical industry. These in-
clude antibacterial agents such as the penicillins, cephalosporins,
aminoglycosides, polyether ionophores, tetracyclines, and other
polyketides ofmany structural types of immunosuppressive agents,
such as the cyclosporins and rapamycin. It is also well-known that
antitumour antibiotics such as daunorubicin, doxorubicin, actino-
mycin, plicamycin, mitomycin, bleomycin, neocarzinostatin and
lidamycin, etc. are the most important among the cancer chemo-
therapeutic agents.3
In 2009 Gupta et al. discovered that salinomycin, one of several
used veterinary antibiotics that belongs to the large class of natu-
rally occurring polyether ionophore antibiotics, is able to kill
cancer stem cells, inhibit breast cancer growth and metastasis in
mice.4 Cancer stem-like cells (CSCs) in different types of cancers
may account for the failure of treatments because they are resis-
tant to many current anticancer therapies.5 Therefore Gupta’s
discovery could be very important for cancer therapy in the future-NC-ND license.and it has inspired many researchers to do further studies and ex-
plore the biological properties of these compounds. On the basis of
the above considerations, the development of novel polyether anti-
biotics and their derivatives as potential antitumour agents is very
attractive. Thus, in this review the properties, mechanism of activ-
ity and potential applications of salinomycin and other polyether
antibiotic in anticancer therapy will be discussed.
Chemical properties of polyether ionophores: The history of the
polyether antibiotics started in 1951 when two compounds nigeri-
cin and lasalocid acid were isolated from different Streptomyces
spp. Since then over 50microorganisms have been found to produce
carboxyl ionophores and over 120 structures have been reported for
this class of compounds.6 The term ionophorewas ﬁrst used in 1967
in reference to the ability of organicmolecules to bindmetal cations
and form lipid soluble complexes that facilitate their transport
across cellular membranes. Ionophores can diffuse from the extra-
cellular space to the intracellular space, and back to the extracellular
space ormay remain in the plasmamembrane as it transportsmetal
ions between intracellular and extracellular spaces.7
Polyether antibiotics show a broad spectrum of biological
activity ranging from antibacterial activity, especially against
Gram-positive bacteria including also antibiotic-resistant S. aureus
and S. epidermidis and other interesting activities such as antifungal,
antiparasitic, antimalarial, antiviral, anti-inﬂammatory and tumour
cell cytotoxic activity.8
Currently, seven carboxylic ionophores are marketed in the USA
and around the world for use as anticoccidial drugs for poultry and
growth promoters in ruminants. These include monensin (Coban,
Rumensin, Coxidin), lasalocid (Avatec, Bovatec), salinomycin
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(Cygro), laidlomycin (Cattlyst) and semduramycin (Aviax).8 The
structures of the most common polyether ionophores and others
discussed here, are presented in Figure 1.
From the chemical point of view polyether antibiotics are mol-
ecules rich in oxygen atoms, that are present at many sites in a
variety of functional groups. (Figs. 1–3). They always contain one
carboxylic group, tetrahydropyran and tetrahydrofuran rings, sev-
eral hydroxyl groups, and a ketone group.9 These groups play a sig-
niﬁcant role in the process of coordination of a monovalent metal
cation, for example, by monensin and salinomycin, and divalent
metal cations for example, by lasalocid.
Recognition of different mechanisms of ion transport by iono-
phore antibiotics is needed to fully understand the mechanism of
action of these compounds, including their anticancer activity.
Knowledge of these mechanisms is very signiﬁcant due to the bio-
logical activity of ionophores having the capacity to transport cat-
ions across cell membranes, thereby disturbing the natural Na+/K+
concentration gradient. The mechanism of transport of a cation by
polyether ionophores is attributed to their ability to exchange pro-
tons and cations in an electroneutral process (Scheme 1).7,9,10 It has
been shown that the polyether ionophore anion (I) forms stableO
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Figure 1. Structures of pcomplexes with monovalent metal cations in which the coordina-
tion of the cations is always accompanied with a pseudo-cyclic
structure stabilised by the ‘head-to-tail’ intramolecular hydrogen
bonds between the carboxylate anion and hydroxyl groups (Figs. 2
and 3). In the electroneutral transport of the cations (M+), the
polyether ionophore anion (I–COO) binds the metal cation (with
preference to Na+ or K+ cations) or proton (H+) to give a neutral salt
(I–COOM+, Figs. 2b and 3b) or a neutral polyether ionophore in
acidic form (I–COOH, Figs. 2a and 3a), respectively, and only un-
charged molecules containing either the metal cation or proton
can move through the cell membrane (Scheme 1a).7,9,10 This mech-
anism is possible in the neutral or slightly alkaline environment of
the cell because it is connected with the deprotonation of carboxyl
group (COOH) leading to a carboxylate group (COO). The microen-
vironment of the tumour is signiﬁcantly different; extracellular
acidic pH is a common characteristic of human tumours while nor-
mal tissues generally have alkaline pH. Tumours are acidic due to
their marked rate of lactic acid production because their cells
maintain a high glycolytic rate even in conditions of adequate
oxygen supply (aerobic glycolysis or ‘Warburg effect’).11 The high
anticancer activity of polyether antibiotics together with the
known acidic conditions in tumour cells inspired Huczynski andOOOOO
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Figure 2. Structures of different types of polyether ionophore complexes presented on the exemplary crystal structures of monensin and its derivatives complexes (ball-and-
stick presentation); (a) monensin acid hydrate;12 (b) monensin acid complex with sodium chloride;12 (c) monensin sodium salt complex37, (d) complex of 1-naphthylmethyl
ester of monensin A with sodium perchlorate;37 (e) complex of N-phenylamide of monensin with sodium chloride;37 (f) complex of N-allylamide of monensin with strontium
perchlorate.40 The solvent molecules and counterions are omitted for clarity.
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of transport of metal cations by polyether ionophores. (Scheme
1b).12
Their studies have shown that the process of cation complexa-
tion occurs in non alkaline environment. The complex is formed
with the polyether ionophore in its acidic form (I–COOH–M+, Figs.
2c and 3c) instead of the polyether ionophore anion (I–COOM+,
Figs. 2b and 3b) and the transport of cations is an electrogenic pro-
cess (Scheme 1b).12 Electrogenic or biomimetic transport mecha-
nisms (Scheme 1) have been also postulated for derivatives of
polyether ionophores with blocked carboxylic function such as
amides and esters (Figs. 2c–e and 3c–e).
Having discussed the chemical principles of biological activity
of polyether antibiotics the anticancer activity of these compounds
will be clearer. Since salinomycin seems to be the most effective
anticancer agent it will be the focus of the next section.
Salinomycin treatment in cancer stem cells and multidrug resis-
tance cells (MDR): The history of discovery of anticancer activity
of salinomycin is very interesting. In 2009 Piyush Gupta and co-
workers tested a large number of 16,000 natural and artiﬁcialcompounds for the ability to kill the stem cell–like cells. From this
screening, 32 candidates were identiﬁed as active but only one of
all tested compounds that is, polyether ionophore antibiotic—
salinomycin, was proved to kill human cancer stem cells (CSCs)
with more than 100-fold efﬁciency relative to that of the
commonly used chemotherapeutic drug—paclitaxel (taxol).4 These
results became a milestone in the ﬁght against CSCs because they
are known to exhibit resistance to a broad spectrum of chemother-
apeutic drugs, thereby surviving current cancer therapies and
initiating long-term tumour recurrence, relapse and metastasis.5
CSCs have been identiﬁed in a variety of human neoplasias, includ-
ing cancers of the breast, brain, bone, skin, liver, bladder, prostate,
colon and pancreas.5 It has been also shown that salinomycin,
contrary to paclitaxel, inhibits the ability of breast CSCs to form
tumours in mice after being treated with 5 mg kg1 salinomycin
daily for ﬁve weeks. The reduction of the tumour mass and
metastasis was accompanied by a reduced number of breast CSCs
and increased epithelial differentiation.5
After Gupta et al. presented these important and innovative
results concerning the anticancer properties and activity of
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Scheme 1. Three mechanisms of the cation transport by the polyether ionophores.
Due to their lipophilic surface, polar inner core containing oxygen atoms and one
carboxylic group, the polyether ionophores are suitable to transport metal cations
across lipid membranes. In the electroneutral transport (a), the metal cation is
incorporated into the polyether skeleton of the pseudocyclic structure of ionophore,
and electroneutral (I-COOM+, Figs. 2c and 3c) complex diffuse to another interface,
where deprotonated ionophore anion I-COO binds with H+ to release M+. The
neutral ionophore acid molecule I-COOH (Figs. 2a and 3a), generated returns. In the
electrogenic transport (b) the metal cation is bound and transported by ionophore
acid molecule I-COOH forming I-COOH+M+ complex (Figs. 2b and 3b). The
biomimetic transport (c) can be realized by polyether ionophores with modiﬁed
carboxylic group such as amides and esters (Figs. 2d–f and 3d–f).
Figure 3. Space-ﬁlling models of the structures presented in Figure 2. The
complexes of polyether ionophores have lipophilic surface and polar inner core
containing oxygen atoms (red). The lipid soluble complexes of the polyether
ionophores (Na+ cation is yellow, Sr2+ cation is magenta) can be moved across lipid
bilayer and cell membrane.
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drug candidate.13
The research group of Cord Naujokat from the University of
Heidelberg has recently investigated the effects of salinomycin
on different human cancer cells, including those that display anti-
cancer drug resistance by different mechanisms. The results of
these studies are very interesting because they show that salino-
mycin has induced massive apoptosis in human cancer cells of
different origin, but not in normal cells such as human T
lymphocytes.14
It has been shown that induction of apoptosis by different anti-
cancer agents essentially depends on the expression of a functional
(wild-type) p53 protein but what is worth noting is that salinomy-
cin-induced apoptosis was independent of the p53 status of the cell.
Different cancer cells were liable to massive apoptosis in response
to exposure to salinomycin demonstrating that salinomycin can
overcome apoptosis resistance due to overexpression and enhanced
proteolytic activity of 26S proteasomes. These studies have shown
clearly that salinomycin is able to induce apoptosis in cancer cells
that exhibit resistance to apoptosis and anticancer agents by over-
expression of Bcl-2, P-glycoprotein or 26S proteasomes with
enhanced proteolytic activity. Salinomycin activates a distinct
apoptotic pathway that is not accompanied by cell cycle arrest
and that is independent of tumour suppressor protein p53, caspase
activation, the CD95/CD95L system and the proteasome. Finally, the
authors of these studies concluded that salinomycin should be con-
sidered as a novel and effective anticancer agent that overcomes
multiple mechanisms of apoptosis resistance in human cancer
cells.14Similar anticancer activity of salinomycin has been observed by
Riccioni et al. who explored the effect of salinomycin on the prolifer-
ation and survival of different clinical multidrug resistance cells
(MDRs) overexpressing P-gp.15 Salinomycin elicited a dose-depen-
dent inhibition of cell growth evident cells: a pronounced inhibitory
effect on cell proliferation was evident at salinomycin concentra-
tions of 1–5 lM.The authors have also evaluated the effect of salino-
mycin on induction of apoptosis of these cells. Salinomycin induced
amoderate pro-apoptotic effect on cancer cells, particularly evident
at days 2–3 of culture and at salinomycin dosages of 1–5 lM.15 Ric-
cioni et al. have performed experiments similar to those reported for
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cin, acts also as a very potent P-gp inhibitor, acting though a
mechanism involving a change in P-gp conformation.15
In studies performed by Naujokat and co-workers the inﬂuence
of salinomycin on leukemia stem cells, which are known to exhibit
multidrug resistance by expression of ATP-binding cassette (ABC)
transporters,was demonstrated.16Oneof themost importantmech-
anismsof drug resistance in different cancer stemcells is the expres-
sion of ATP-binding cassette (ABC) transporters which belong to a
highly conserved superfamily of transmembrane proteins capable
of exporting a wide variety of chemotherapeutic drugs from the
cytosol, thereby conferring multidrug resistance which is a major
obstacle in the success of cancer chemotherapy.17
Therefore, studies showing salinomycin having activity on this
typeof leukaemia stemcellswere important to verify that salinomy-
cin can be regarded as a novel and effective agent for the elimination
of leukaemia stem cells. It has been proved that salinomycin is able
to overcome ABC transporter-mediated multidrug and apoptosis
resistance inhuman leukaemia stemcell-like cells that exhibit resis-
tance to a broad spectrum of chemotherapeutic drugs by virtue of
expression of functional ABC transporters.16 The uncommon apop-
totic pathway14 and the breakdown of ABC transporter-mediated
multidrug and apoptosis resistance by salinomycin16 may also
contribute to the inability of leukemia stem cell-like cells to adapt
to apoptosis-inducing concentrations of salinomycin.
Other studies described the ability of salinomycin to inhibit the
Wnt signalling cascade. Because the Wnt/b-catenin signal trans-
duction pathway plays a central role in stem cell development,
and its aberrant activation can cause cancer drugs targeted at the
Wnt/b-catenin pathway may be useful as anticancer agents.18 It
has been demonstrated that even nanomolar concentrations of
salinomycin can inhibit Wnt1-induced signalling, but at this
concentration the drug had very little effect on reporter gene activ-
ity in cells that overexpressed Fzd5/LRP6 or b-catenin. Much higher
concentrations (4 lM) of salinomycin were needed to block the
Wnt signalling induced by the downstream activators. Thus,
salinomycin can suppress Wnt signalling by at least two different
mechanisms, depending on drug dosage. It has been shown that
the calcium polyether ionophore—ionomycin also strongly inhib-
ited Wnt pathway activation by Fzd5/LRP6 at concentrations at
which salinomycin was ineffective. Incubation of the malignant
lymphocytes with ionomycin induced apoptosis within 48 h, with
a mean IC50 of 230 nM. Under the same conditions, salinomycin
failed to induce apoptosis in peripheral blood mononuclear cells
(PBMCs) at a 100-fold higher concentration. This result suggests
that salinomycin has selective cytotoxicity to CLL cells that are
known to depend on Wnt signalling.18
Different studies have shown that salinomycin reduced the pro-
portion of CD133+ cell subpopulations within colorectal cancers
(CRC) which have been identiﬁed as cancer stem like cells (CSCs).19
It is believed that many CRC therapies, that kill the bulk of cancer
cells, inevitably fail because they do not eliminate colorectal CSCs,
which survive to regenerate new tumours. Furthermore, salinomy-
cin treatment decreased colony-forming ability and cell motility in
human colon carcinoma cells (HT29). For the ﬁrst time these studies
have shown that salinomycin not only targets CRC stem cells specif-
ically but also decreases the invasion andmigration of CRC cells. In-
deed, the latter effect seems especially attractive becausemore than
90% of cancer-related mortality arises from cancer invasion and
metastasis.19 Moreover it is important to emphasize that IC50 analy-
sis has clearly demonstrated that CSCs aremore resistant not only to
paclitaxel4 but also toother conventional anticancerdrugs suchas5-
ﬂuorouracil (5-FU) and cis-diamminedichloroplatinum (cisplatin),
but they are sensitive to salinomycin.20
Synergistic anticancer effect of salinomycin combined with anti-
cancer drugs: Very recent studies performed by Zhi et al. and Kimet al. have demonstrated the ability of salinomycin to sensitize
cancer cells treated by commonly used anticancer drugs such as
paclitaxcel, docetaxcel, vinblastin, colchicines and also proved that
salinomycin increased the sensitivity of cancer cells to the apopto-
tic effects of doxorubicin or etoposide.20 It was shown that the abil-
ity of salinomycin to sensitize cancer cells to the effects of
doxorubicin or etoposide is associated with an increase in DNA
damage and a decrease in anti-apoptotic protein p21 levels. Next
study has proved a novel mechanism of salinomycin sensitization
in radiation-treated cancer cells by inducing G2 arrest and causing
DNA damage and reduced p21 levels. Thus, it is clearly indicated
that the mechanism underlying salinomycin sensitization is con-
served in both chemo- and radiation-treated cells.20
Sensitization to the antimitotic drugs could be achievedwith very
low concentrations of salinomycin, suggesting that there is a possi-
bility to minimize salinomycin toxicity associated with human can-
cer patient treatments. It has been shown that sensitization by
salinomycin increased apoptosis and sensitized the cancer cells to
antimitotic drugs by preventing G2 arrest, suggesting that salinomy-
cin contributes to the induction of mitotic catastrophe. These results
may contribute to the development of salinomycin-based
chemotherapy for patients treated with antimitotic drugs.20 The
synergistic anticancer effect of salinomycin combined with gemcita-
bine in human pancreatic cancer cells has been also investigated. It is
now well-documented that salinomycin inhibited the growth of
CSCs,4,13,16 while gemcitabine suppressed the viability of non-CSCs.
Consistently, in vivo studies showed that salinomycin combined
with gemcitabine could eliminate the engraftment of human pancre-
atic cancer more effectively than the individual agents. These data
have indicated that administration of salinomycin, which targets
CSCs, may constitute a potential therapeutic strategy for improving
the efﬁcacy of gemcitabine to eradicate pancreatic cancer.21
Effects of salinomycin on apoptosis: Recent studies performed on
prostate cancer cells have evidenced that salinomycin induces
apoptosis of these cancer cells by elevating oxidative stress
through intracellular reactive oxygen species (ROS) production,
which leads to the disruption of mitochondrial function and subse-
quent release of cytochrome c to the cytosol, and activation of the
caspase zymogen cascade.22 Apoptotic signals originating from
mitochondria include a change in the electron transport system,
loss of mitochondrial membrane potential (MMP, DWm), failure
of Ca2+ ﬂux homeostasis, generation of ROS, and release of caspase
activators. The link between ROS and apoptosis in salinomycin-ex-
posed cells has been evident from the inhibition of apoptosis in
pre-treated of cancer cells by antioxidant N-acetylcysteine. The
study has also indicated that the chemo-resistance of hormone-
independent cancer cells to salinomycin is higher than that of hor-
mone-dependent cells, and compared to cancer cells, non-malig-
nant prostate cells are relatively more resistant to salinomycin.22
In 2012 Ketola et al. demonstrated that salinomycin inhibits
growth and migration of prostate cancer cells by reducing the
expression of key prostate cancer oncogenes, inducing oxidative
stress, decreasing the antioxidative capacity and cancer stem cell
fraction.23 Salinomycin was most effective in inhibiting vertebral-
cancer of the prostate cells (VCaP) at half maximal effective con-
centration (EC50) 380 nM. The authors also proved other interest-
ing activity of salinomycin, for example, the fact that it reduced
the migration of cancer cells. As the EC50 value of salinomycin in
prostate carcinoma cells (PC-3) in response to 48-h exposure was
higher than 1 lM, the salinomycin-induced anti-migratory effect
is not due to inhibition of cell proliferation. The ability of salinomy-
cin to inhibit prostate cancer cell growth and cancer stem cell pop-
ulation, without major effects on non-malignant prostate epithelial
cells, is due to the induction of oxidative stress and the reduction of
antioxidative properties. Thus, salinomycin and its derivatives may
provide a novel selective approach to prostate cancer therapy.24
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(MDR): Resistance to chemotherapy is a common clinical problem
of patients with cancer. During treatment, tumour or neoplastic
cells are often found to be refractory to a variety of drugs with dif-
ferent structures or modes of actions. Therefore, the search for new
drugs is of vital importance. The numerous potential candidates re-
ported so far include polyether ionophores. The speciﬁc effect of
these compounds on cancer cells involves increasing their sensitiv-
ity to chemotherapy and the ability to reverse multidrug resistance
(MDR) in human carcinoma. Nearly two decades ago the effect of
several polyether antibiotics on colchicine resistance in human
carcinoma multidrug-resistant KB-C410 cells, which exhibit about
4000-fold resistance to colchicine, was studied. The results of these
studies demonstrated that 4 out of 14 polyether antibiotics are
able to reverse colchicine resistance. Among them, laidlomycin
was the most potent. It potentiated colchicine cytotoxicity on
KB-C4 cells by about 700-fold at 1 lg/ml. The degree of potentia-
tion was calculated by dividing the half maximal inhibitory
concentration value (IC50) of colchicines in the absence of the poly-
ether antibiotic by the IC50 value of colchicine in the presence of
the polyether antibiotic.25
Anticancer activity of inostamycin: Earlier studies have shown
that another polyether antibiotic—inostamycin—can also reverse
MDR in human carcinoma KB-C4 cells. The mechanism of its action
was studied by the use of radioactively labelled vinblastine, a well
known antimicrotubule drug used to treat certain kinds of cancers.
Inostamycin dose-dependently increased the accumulation of vin-
blastine in multidrug-resistant KB-C4 cells at 0.5–2 lg/ml, while
it did not enhance accumulation in the drug-sensitive KB-3-1 cells.
At a concentration of 1 lg/ml inostamycin inhibited active vinblas-
tine efﬂux fromKB-C4 cells, but not fromKB-3-1 cells, and inhibited
vinblastine binding to KB-C4membranes with an IC50 of 0.94 lg/ml
Furthermore, vinblastine accumulated by treatment with 1 lg/ml
of inostamycin was resistant to efﬂux from KB-C4 cells, even after
the removal of inostamycin.26
The accumulation of vinblastine for 1 h in Kb-C4 cells increased
about 4 times in the presence of inostamycin 1 lg/ml. The accumu-
lation increased 3 times even after the cells had been pre-incu-
bated with inostamycin for 30 min and then inostamycin was
washed out. Detailed study has indicated that inostamycin irre-
versibly bound to KB plasma membranes, but the binding capacity
did not parallel the amount of P-glycoprotein in three KB cell lines.
Inostamycin was found to interact speciﬁcally with puriﬁed phos-
phatidylethanolamine. These results suggest that inostamycin can
irreversibly inhibit P-glycoprotein by irreversibly binding to plas-
ma membranes through phosphatidylethanolamine.27
The anticancer activity of inostamycin was very promising,
therefore studies using this compoundwere continued. To establish
whether the cytostatic effect of inostamycin is restricted to lung
carcinoma cell lines or applicable to other type of cells, ﬁve oral
squamous carcinoma (SCC) cell lines have been tested. Cell growth
was suppressed by 62.5–125 ng/ml inostamycin, with non-viable
cells being <1%, indicating inostamycin is cytostatic to SCC cell
lines. Moreover, inostamycin induced an increase in G1/G0 cells
(1.2- to 3.2-fold) over 24 h. These results suggest that inostamycin
is a useful agent to prevent recurrences of tumour for oral SCC.28
On the other hand, it was shown that inostamycin is an inhibi-
tor of cytidine 50-diphosphate 1,2-diacyl-sn-glycerol (CDP-DG):
inositol transferase. It signiﬁcantly reduced epidermal growth fac-
tor (EGF)-induced in vitro invasion of the tongue carcinoma cell
lines indicating that inostamycin would be useful for an anti-inva-
sive agent in tongue cancer.29
It was also found that inostamycin increased the ability of pac-
litaxel (taxol) to induce apoptosis in Ms-1 cells.30 A considerably
higher concentration of paclitaxel was required for the induction
of apoptosis in Ms-1 cells than in other cell lines tested. Treatmentof Ms-1 cells with inostamycin, reduced the dosage of paclitaxel
required to induce cell death by apoptosis. This effect of inostamy-
cin is speciﬁc to Ms-1 cells and inostamycin did not increase the
cytotoxicity of other antitumor drugs such as adriamycin, vinblas-
tine, methotrexate, cisplatin, etoposide, or camptothecin in Ms-1
cells. Thus, inostamycin is a chemosensitizer of paclitaxel in small
cell lung carcinoma Ms-1 cells.31
Furthermore, inostamycin abrogated the stimulatory effect of
VEGF (vascular endothelial growth factor) on growth and migra-
tion activities of endothelial cells by targeting extracellular sig-
nal-regulated kinase-cyclin D1 and p38 pathways, respectively.
Because inostamycin has antiproliferative and anti-invasive abili-
ties, inhibition of phosphatidylinositol synthesis could be a potent
therapeutic strategy against cancer as the cancer dormant therapy,
that is persistence of residual tumor cells for long periods. Inosta-
mycin, also induced activation of caspase-3(-like) proteases and
apoptosis showing that it should be recognized as a potential
anticancer drug.32
Anticancer activity of monensin: The antineoplastic effect of an-
other polyether antibiotic, monensin, was also studied in depth.
The antiproliferative effect of monensin on human lymphoma cell
lines and SNU-C1 colon cancer cells, as well as NCI-H929 myeloma
cells, showed thatmonensin signiﬁcantly inhibited the proliferation
of all the cell lines examined with a 50% inhibition in concentration
of about 0.5 lM, and induced a G1 and/or a G2-M phase arrest in
these cell lines.33 Furthermore,monensin inducedapoptosis in these
cell lines. Detailed studies indicate that monensin inhibited the cell
proliferation of human lymphomacell lines bynot only inducing cell
cycle arrest, but also by triggering apoptosis through the loss of
mitochondrial transmembrane potential (MMP,m). Finally, these re-
sults suggest thatmonensinmay be useful as a novel investigational
drug for the treatment of lymphoma patients.33
Recently monensin has been shown to potentiate the in vitro
cytotoxicity of immunotoxins, ribonuclease and overcome the drug
resistance.34 For example, these studies demonstrated that immu-
notoxin SWA11-ricin A chain could selectively eliminate almost
99.9% of clonogenic tumour cells at a concentration of 1  10
8 M and the cytotoxic activity of SWA11-ricin A chain was poten-
tiated 100-fold in the presence of the carboxylic ionophore monen-
sin at 1  107 M. Furthermore, the kinetic studies revealed that
monensin two-fold enhanced the rate of protein synthesis inhibi-
tion and eliminated the lag phase suggesting a rapid effect on
either the rate or route of internalisation.34 It was also indicated
that monensin is by itself a potent inhibitor of proliferation of both
KB parent and KB/multidrug resistant (MDR) cells. In the presence
of monensin, the ID50 of doxorubicin against KB/MDR cells after a
72 h drug exposure was about 5-fold, reduced while the presence
of monensin did not signiﬁcantly alter doxorubicin cytotoxicity
against KB parent cells. In 1 h experiment, the presence of monen-
sin by about two- to threefold increased the intracellular accumu-
lation of doxorubicin in KB/MDR cells but not in KB parent cells.
Monensin also markedly reduced doxorubicin efﬂux from KB/
MDR cells. These results indicated that reversal of MDR by monen-
sin may be due to facilitation of drug transport and subsequent
enhancement of DNA damage in MDR cells.34 Detailed studies
proved that Monensin reduced drug efﬂux but did not alter subcel-
lular distribution of daunorubicin, consistently with the view that
monensin acts directly on P-glycoprotein in MDR cells.34
The lipophilicity and short half-life of monensin precludes its
use and a suitable drug delivery system is needed to obtain the de-
sired in vivo effects. Therefore, in several studies interesting
delivery systems for monensin, such as long circulating liposomes
and nanoparticles, have been developed. It has been shown that
the delivery of monensin via long-circulating nanoparticles in-
creases the in-vitro cytotoxicity of anticancer drugs and immuno-
toxins, as well as that long-circulating monensin liposomes
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noma (MCF-7/dox) cells.35 The effects of monensin liposomes on
drug resistance reversal, induction of apoptosis and expression of
multidrug resistance (MDR) genes in a doxorubicin-resistant hu-
man breast tumour (MCF-7/dox) cell line have been evaluated.
MCF-7/dox cells were treated with various anticancer drugs (doxo-
rubicin, paclitaxel and etoposide) alone and in combination with
monensin liposomes. The results of these studies indicated that
monensin liposomes overcame drug resistance in MCF-7/dox cells
to doxorubicin, etoposide and paclitaxel by 16.5, 5.6 and 2.8-times,
respectively. The combination of doxorubicin (2.5 lg/mL) with
monensin liposomes (20  108 M) induced apoptosis in approxi-
mately 40% cells, whereas doxorubicin (2.5 lg/mL) or monensin
liposomes (20  108 M) alone produced minimal apoptosis
(<10%) in MCF-7/dox cells. In conclusion, the result is that monen-
sin liposomes potentiated the in vitro cytotoxicity of anticancer
drugs in MCF-7/dox cells and offered an effective solution to over-
come drug resistance in vitro. However, further in vivo studies are
needed to conﬁrm this in vitro ﬁndings.35
Grifﬁn et al. studied the ability of monensin incorporated in
unilamellar vesicles (liposomes) to potentiate antitumour immu-
notoxins in vitro and in vivo.36 In their experiments monensin
was incorporated into liposomes and used in combination with
speciﬁc immunotoxins against human tumour cell lines in vitro
(against H-MESO-1 malignant mesothelioma, LS174T colorectal
carcinoma, and U373, U87, and MG-1 glioblastomas) and in vivo
(mice were inoculated intra-peritoneally with H-MESO-1 cells).36
These studies have shown that immunotoxin (speciﬁc ricin A-
chain) plus 0.1 lM liposomal monensin was 5-fold more toxic for
H-MESO-1 cells and 1000-fold and 2200-fold more toxic for human
glioblastoma U373 and U87 cells respectively, than immunotoxin
plus 0.1 lM free monensin in buffer. In vivo studies (in mice) lipo-
somal monensin in combination with immunotoxin substantially
prolonged survival, and three (21%) of 14 mice bearing H-MESO-
1 xenografts treated with the liposomes showed no evidence of tu-
mour on day 160 after treatment. Treatment with controlled
immunotoxin plus liposomal monensin was ineffective.36 These
ﬁndings clearly suggest that encapsulation of monensin into lipo-
somes increased the capacity of monensin to enhance the potency
of cell-speciﬁc immunotoxin in vitro and in vivo.
The results of recent studies performed by Ketola et al. have
indicated also that monensin is one of the most potent and can-
cer-speciﬁc inhibitors in a systematic sensitivity testing of most
well known drugs and drug-like molecules in a panel of prostate
cancer cell models.37 The authors have screened 4910 known drugs
and drug-like molecules in cancer cell lines to identify new pros-
tate cancer cell growth selective inhibitors. The study indicated
that only four compounds, including monensin, selectively inhib-
ited cancer cell growth at nanomolar concentrations.37 They
proved that monensin effects at nanomolar concentrations are
linked to induction of apoptosis and potent reduction of androgen
receptor mRNA and protein in prostate cancer cells. Monensin also
elevated intracellular oxidative stress in prostate cancer cells.
Importantly, the antiproliferative effects of monensin were poten-
tiated by combinatorial treatment with the antiandrogens. Taken
together, the results suggest that monensin is a potential, well-tol-
erated, in vivo compatible drug with strong proapoptotic effects in
prostate cancer cells, and synergistic effects with antiandrogens.37
These studies suggest a general strategy in which the effects of
antiandrogens could be enhanced by combinatorial administration
with agents that increase oxidative stress in prostate cancer. The
result of studies performed by Ketola et al. suggested that monen-
sin,37 as well as salinomycin,22 should be recognized as new poten-
tial agents against prostate tumours.
Activity of polyether antibiotic derivatives: During the last decade,
Huczyn´ski et al. obtained many derivatives of two ionophores:monensin and lasalocid, and studied their structures and their
complexes with metal cations and amines.38 Recently, they also
proved that some new polyether ionophore derivatives also show
relatively high antibacterial activity, including against antibiotic-
resistant S. aureus and S. epidermidis.39 Modiﬁcation of the carbox-
ylic group of monensin leads to amides and esters which show very
interesting and unexpected properties. For example, monensin
methyl ester is able to form a proton channel which is thought
to be able to transport protons through the cell membrane and is
a suitable model for studying proton-transfer processes.40 More-
over, new esters and amides of monensin are able to form stable
complexes with divalent metal cations while unmodiﬁed monen-
sin forms complexes only with the monovalent cation.41 Modiﬁca-
tion of the carboxylic group of polyether ionophores should change
the mechanism of ion transport through the cell membrane from
electroneutral for acidic polyether ionophores to an electrogenic
process for their amides and esters12 which is important in view
of the Warburg effect disused above.11
On the basis of this experience, and inspired by the high anti-
cancer activity of salinomycin discovered by Gupta et al.4 this
group recently synthesized some amides of this antibiotic and
evaluated their anticancer activity.42 The antiproliferative activity
of salinomycin and its derivatives were examined on four human
cancer cell lines including vincristine-resistant and doxorubicin-
resistant cell lines indicating that salinomycin and its derivatives
break down drug resistance in the cancer cells. It is very important
to note that almost all analogues of salinomycin showed stronger
activity then unmodiﬁed salinomycin against drug resistant cell
line what suggested breaking down drug-resistance of the tested
cell line by these derivatives. These results show that salinomycin
is a promising tool to reverse the MDR phenotype in clinic and to
treat apoptosis resistant cancers and that modiﬁcation of salino-
mycin can lead to more anticancer active compounds. Very re-
cently this group also found that lasalocid and its complexes
with amines are strong cytotoxic agents towards cancer cell lines.
The cytostatic activity of these compounds is greater than that of
cisplatin, indicating that lasalocid and its complexes are promising
candidates for new anticancer drugs.43
Perspectives: Polyether ionophores are typical veterinary antibi-
otics and have never been used as antibiotic in humans, probably
due to the considerable toxicity observed in mammals. In general,
the marketed polyether ionophores have been found to be safe
and effective in the target animal species within the approved dos-
age ranges.44 However, overdosage, misuse and drug interactions
have resulted in the ionophore toxic syndrome. Their toxicity is
characterized clinically by anorexia, diarrhoea, dyspnoea, depres-
sion, ataxia, death, pathological changes and by degeneration and
necrosis of heart and skeletal muscles. For example, the oral NOELs
for monensin (no observable effect levels) were approximately
2–3.8 mg/kg in rats and 5 mg/kg/day in dogs after subchronic oral
dosing of 3 months, 1.25 mg/kg/day in dogs after chronic oral dosing
for 1 year, and 1.4 mg/kg/day in rats and 1.3 mg/kg/day inmice after
chronic oral dosing for 2 years.44
No studies have been reported in which humans were inten-
tionally exposed to polyether ionophores. Nonetheless, some of
them have been tested in in vitro and in vivo animal models for
the treatment of human malaria45 and as sensitizers for immuno-
toxin and anticancer drugs.21,36
Assuming that the above uses of ionophore antibiotics would
pass clinical trials and given regulatory approval, the potential ben-
eﬁts to humankind should far outweigh the risks of the low-level
human exposures. It cannot be overemphasized that therapeutic
doses for humans would be many folds lower than the single and
repeated doses that are toxic for animals.
As discussed above, results of many studies have shown that
both cancer stem cells (CSC) and multidrug-resistant cancer cells
A. Huczyn´ski / Bioorg. Med. Chem. Lett. 22 (2012) 7002–7010 7009(MDR) are effectively killed by polyether ionophores particularly
by salinomycin. The investigation of polyether ionophores safety,
toxicity, pharmacology and anticancer activity in humans is a chal-
lenge for the coming years. The chemotherapy approach is based
on compounds that exert greater selective toxicity against cancer
cells (including CSC and MDR cells) compared with that against
other cells in the mammalian host. The activity of these com-
pounds should be further studied in vitro to specify their mecha-
nisms of action and in vivo to assess their activities and
tolerance in the different types of cancer.
All the above discussed results show that polyether ionophores
are currently well-recognized candidates to be clinically tested as
anticancer drug candidates. The exact mechanism of anticancer
activity of polyether antibiotics still has to be worked out. The
studies performed so far have shown that these compounds affect
cancer cells in a special way by increasing their sensitivity to che-
motherapy (monensin, salinomycin, inostamycin) and reverse
multidrug resistance (laidlomycin, monensin) in human carci-
noma. Furthermore, these compounds have been found to be cyto-
toxic to the human carcinomamultidrug-resistant cells (monensin,
salinomycin). Ionophore antibiotics also inhibit chemoresistant
cancer cells by increasing apoptosis but up to now only salinomy-
cin has been successfully able to kill human cancer stem cells
(CSCs). Therefore, at present polyether antibiotics should be con-
sidered as new anti-cancer drugs for cancer chemoprevention
and cancer therapy. I am convinced that the studies of the struc-
ture, chemical modiﬁcation and anticancer activity of this group
of compounds will increase in the near future and will provide
more effective therapeutics for cancer treatment.
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